To ensure long-term clinical efficacy and treatment compliance, avoiding severe off-target side effects is vital to maintaining patient well-being, Prof. Weisel stressed. “We got rid of off-target effects which are hampering life quality like fatigue, like GI toxicity,” she said. “So I think it’s a regimen reflecting the needs of the patients.”

In this multiple myeloma roundtable from EHA 2026, the roundtable panelists evaluate the strategic sequencing of mezigdomide-based therapy, its potential as a bridging strategy, and its practical logistical advantages in community-based practices compared to T-cell redirecting therapies.

Clinical investigators are actively evaluating these novel agents across several strategic combinations and settings, Prof. Weisel explained.
“We have very interesting maintenance trials,” she noted, “where iberdomide is tested as a monotherapy or even in combination with monoclonal anti-CD38 antibodies.”

Dr. Dimopoulos reviews the clinical efficacy of adding the novel cereblon E3 ligase modulator (CELMoD), mezigdomide, to carfilzomib and dexamethasone (MeziKd) for patients with relapsed or refractory multiple myeloma, explaining how this combination significantly extends progression-free survival timelines for an increasingly high-risk, triple-class-exposed population.